Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
CDMO: EUROAPI Supports Sanofi’s mRNA Vaccine Platform with The Development of Lipid Nanoparticles
Details : EUROAPI will focus on lipids that are currently being tested as part of Phase I/II clinical trials that will support Sanofi’s mRNA vaccines platform, targeting indications including Flu.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
May 30, 2022
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : MRT5500
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi and Translate Bio initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate
Details : The Phase 1/2 clinical trial is a randomized, double blind and placebo-controlled trial designed to evaluate the safety, reactogenicity (tolerability) and immunogenicity (immune response) of MRT5500, a COVID-19 vaccine candidate.
Product Name : MRT5500
Product Type : Vaccine
Upfront Cash : Inapplicable
December 03, 2021
Lead Product(s) : MRT5500
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Protein-Based COVID-19 Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi and GSK Delay Their Adjuvanted Recombinant Protein-Based Covid-19 Vaccine Program
Details : In a phase I/II study of Sanofi/GSK’s adjuvanted recombinant protein-based vaccine, interim results found the vaccine induced an immune response comparable to recovered COVID-19 patients in adults aged 18 to 49 years.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 12, 2020
Lead Product(s) : Protein-Based COVID-19 Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Gavi
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Sanofi and GSK intend to make available 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine, if approved by regulatory authorities and subject to contract, to the COVAX Facility.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 28, 2020
Lead Product(s) : COVID-19 Vaccine, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Gavi
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : COVID-19 Vaccine, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : European Union
Deal Size : Undisclosed
Deal Type : Agreement
Sanofi and GSK Will Provide Up To 300 Million Doses of COVID-19 Vaccine to the European Union
Details : Agreement supports scale-up of manufacturing capabilities in several European countries . The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technolo...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
September 18, 2020
Lead Product(s) : COVID-19 Vaccine, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : European Union
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : European Union
Deal Size : Undisclosed
Deal Type : Partnership
Sanofi, Glaxosmithkline in Talks with EU to Secure Covid-19 Vaccine Deal
Details : The vaccine candidate developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 31, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : European Union
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : US Department Of Health And Human Services
Deal Size : $2,100.0 million
Deal Type : Collaboration
Details : Collaborating with the U.S. Department of Health and Human Services and Department of Defense will help fund the development activities and secure scale-up of Sanofi’s and GSK’s manufacturing capabilities in the U.S for the recombinant protein-based,...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 31, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : US Department Of Health And Human Services
Deal Size : $2,100.0 million
Deal Type : Collaboration
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : UK Government
Deal Size : Undisclosed
Deal Type : Agreement
Sanofi/GSK Sign Deal with UK Gov for COVID-19 Vaccine
Details : The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant technology.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 29, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : UK Government
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : COVID-19 Vaccine, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 09, 2020
Lead Product(s) : COVID-19 Vaccine, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
